NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
M.D. Anderson Cancer Center
Intergroupe Francophone de Cancerologie Thoracique
Institute of Cancer Research, United Kingdom
Fondazione per la Medicina Personalizzata